Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$40.37M-26.4%-$31.93M-26.8%-$25.18M+21.7%-$32.13M+15.8%-$38.17M+18.8%
$9K0.0%$9K-25.0%$12K+1,100%$1K-75.0%$4K-50.0%
$7.41M-21.2%$9.4M+119%$4.3M+10.3%$3.9M+60.8%$2.42M+92.9%
-$24.08M+28.4%-$33.65M-52.1%-$22.12M-9.7%-$20.16M-7.5%-$18.76M+17.1%
$3K-94.7%$57K-56.5%$131K+2,520%$5K
-$8.47M+91.4%-$98.16M+34.0%-$148.71M-1,045%-$12.99M-201%$12.85M-2.1%
-$795K-100%$170.16M$0-100%$191.31M+27,430%-$700K-101%
-$33.35M-187%$38.33M+122%-$170.84M-200%$171.01M+979%-$19.46M-128%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Jade Biosciences, Inc. Common Stock generate?
Jade Biosciences, Inc. Common Stock (JBIO) generated -$100.0M in operating cash flow over the trailing twelve months.
What is Jade Biosciences, Inc. Common Stock's free cash flow?
After $196.0K of capital expenditures, Jade Biosciences, Inc. Common Stock's free cash flow was -$94.9M over the trailing twelve months, down 66.7% year over year.
Where does Jade Biosciences, Inc. Common Stock's cash flow data come from?
Every line is extracted from Jade Biosciences, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.